In conclusion, this study found that GS-Rd regulates APP transcription through the MAPK pathway to reduce Aβ mRNA levels, thereby reducing the production of Aβ and ROS in AD and providing a new target for the treatment of AD. This evidence concerns the gene APP and Alzheimer disease.